IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

Core Insights - IMUNON, Inc. is hosting an R&D Day on November 10, 2025, to discuss its DNA-mediated immunotherapy, IMNN-001, which is in Phase 3 development for advanced ovarian cancer treatment [1][2] - The event will feature presentations from leading investigators involved in the clinical trials, highlighting the urgent need for new treatment options in ovarian cancer [2][7] - IMUNON aims to bring innovation to ovarian cancer treatment, which has not seen significant advancements in approximately 30 years [2] Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases [4] - The company is advancing its non-viral DNA technology, with its lead clinical program, IMNN-001, being a DNA-based immunotherapy for advanced ovarian cancer [5] - IMNN-001 instructs the body to produce cancer-fighting molecules at the tumor site and has completed multiple clinical trials, including a Phase 2 trial and is currently in a Phase 3 trial [5] Clinical Trials and Research - The OVATION 2 trial data presented will include survival benefits and address the unmet needs in ovarian cancer treatment [7] - The Phase 2 minimal residual disease (MRD) study results will provide insights into immune activation mechanisms [7] - The statistical design of the Phase 3 trial and the path to approval will be discussed, along with enrollment momentum and clinical milestones [7]